However, manageable clinical safety profiles are now being established for pan-AKT inhibitors administered alone and in combination with established taxane-based or androgen/AR-targeted therapies, with patient responses linked to dysregulated PTEN/PI3K signaling in several solid tumors (including prostate cancer) [199,200,201,202,203,204,205]. Here, AKT1 is linked to prostate carcinoma.